GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Average Price Target of $4.23

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $4.23.

Several equities analysts recently weighed in on the stock. UBS Group increased their price target on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. TD Cowen raised their target price on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Citigroup boosted their target price on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th.

GoodRx Stock Performance

NASDAQ GDRX opened at $3.25 on Friday. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 81.27, a PEG ratio of 1.63 and a beta of 1.69. The company has a fifty day moving average price of $3.45 and a 200-day moving average price of $2.90. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same period last year, the company posted $0.09 earnings per share. GoodRx’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, equities research analysts predict that GoodRx will post 0.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 2,760,995 shares of company stock worth $9,673,207 in the last three months. 5.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Corient Private Wealth LP bought a new position in shares of GoodRx in the second quarter worth $86,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in GoodRx in the 2nd quarter worth about $500,000. Headlands Technologies LLC purchased a new stake in shares of GoodRx in the second quarter worth about $30,000. Technology Crossover Management X Ltd. purchased a new stake in shares of GoodRx in the second quarter worth about $4,762,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of GoodRx in the second quarter worth about $540,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc operates a healthcare technology platform that helps consumers find prescription medications at lower prices. Through its website and mobile applications, GoodRx allows users to compare prescription prices at participating pharmacies, access discount coupons and identify potential savings on commonly prescribed medications. The company’s services are primarily focused on the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as telehealth services that connect consumers with healthcare providers for certain medical consultations and prescriptions.